Meet the Expert: Using Diabetes Tech to Improve Patient Care
Priya Prahalad, MD, PhD, is a Clinical Associate Professor of Pediatrics and Medical Director of Clinical Informatics at Stanford Children’s…
Status Update: Connected Insulin Delivery Devices
Do these stats surprise you? Of the 1.6 million people with type 1 diabetes in the US,1 only 30 to…
A Guide to CGMs and Medicaid Coverage Differences by State
Continuous Glucose Monitors (CGMs), the small devices that many people with diabetes wear on their bodies, are incredible tools for…
Latest News on CGM and Dexcom Straight from the CEO, Kevin Sayer
T1D Exchange recently took advantage of the golden opportunity to interview Kevin Sayer, chairman, president and CEO of Dexcom. In…
Bigfoot Unity Cleared and Ready to Step Out: Interview with Jeffrey Brewer, CEO, Bigfoot Biomedical
On May 10, 2021 Bigfoot Biomedical Inc. received FDA Clearance for its Bigfoot Unity Diabetes Management System. Jeffrey Brewer is…
Innovations in T1D Tech: Highlights from the ATTD Conference
Every year the Advanced Technologies & Treatments for Diabetes (ATTD) conference brings together diabetes researchers from all over the world….
Chatting with Dexcom CEO About the New G7, the Sampling Program, and the Patient Voice
There are approximately 900,000 people across the globe wearing a Dexcom continuous glucose monitor (CGM) today. “Up from 600,000 at…
Life with the DIY Loop
I’ve lived with type 1 diabetes for the past 20 years, and in that time frame, managing my diabetes has…
Closed-Loop Study with Tandem “Artificial Pancreas” Showed Promising Results in Children
A 16-week, multi-center, randomized trial of over 100 children aged 6 to 13 at sites around the U.S. showed improved…
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
